Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Collaborator: Shanghai Sankyo Pharmaceuticals Co., Ltd.
• Treatments: Losartan; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmHg and <110 mmHg, mean seated systolic blood pressure < 180 mmHg)

• able to give written informed consent

Exclusion Criteria:

• known or suspected secondary hypertension

• history of chronic hepatic diseases

• obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease

• cardiac arrhythmia

• unstable angina pectoris

• congestive heart insufficiency (New York Heart Association classification III-IV)

• bilateral renal artery stenosis

• isolated renal artery stenosis

• post renal transplantation

• history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment

• retina bleeding/effusion

• insulin dependent diabetes mellitus

• uncontrolled non-insulin dependent diabetes mellitus